TScan Therapeutics (TCRX) Revenue (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Revenue data on file, last reported at $982000.0 in Q1 2026.

• On a quarterly basis, Revenue fell 54.77% year-over-year to $982000.0 in Q1 2026; TTM through Mar 2026 was $9.1 million, a 106.65% increase from a year earlier, with the FY2025 full-year figure at $10.3 million, up 266.65% from the prior year.
• Revenue for Q1 2026 stood at $982000.0, down from $2.6 million in the prior quarter.
• Over the last five years, Revenue for TCRX reached as high as $7.2 million in Q4 2023 and fell as low as $536000.0 in Q2 2024.
• Historically, Revenue has averaged $2.8 million across 5 years, with a median of $3.0 million in 2022.
• Across the five-year window, Revenue slumped 90.78% in 2024 and soared 473.88% in 2025, its largest moves.
• Year by year, Revenue stood at $3.1 million in 2022, then surged by 132.99% to $7.2 million in 2023, then slumped by 90.78% to $665000.0 in 2024, then jumped by 286.02% to $2.6 million in 2025, then plunged by 61.75% to $982000.0 in 2026.
• Per Business Quant data, the three most recent Revenue figures were $982000.0 in Q1 2026, $2.6 million in Q4 2025, and $2.5 million in Q3 2025.